• Online Features  This Article  • Full text  • PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Retinal/ Chorioretinal Disorders  • Ocular Imaging  • Alert me on articles by topic  Social Bookmarking   What's this?

Mohammedyusuf E. Hajee, MD; Wayne F. March, MD; Douglas R. Lazzaro, MD; Arthur H. Wolintz, MD; Eric M. Shrier, DO; Sofya Glazman, MD; Ivan G. Bodis-Wollner, MD, DSc

Arch Ophthalmol. 2009;127(6):737-741.

Objective  To quantify retinal thickness in patients with Parkinson disease (PD).

Methods  Forty-five eyes of 24 PD patients and 31 eyes of 17 control subjects underwent a comprehensive ophthalmologic examination. We used optical coherence tomography to examine retinal thickness, separately quantifying the inner and outer retinal layers. Intraocular pressure was measured by Goldmann applanation tonometry.

Results  The mean (SD) ages of the patients with PD and healthy subjects were 64.0 (6.5) years vs 63.5 (10.7) years (P = .77). The mean (SD) intraocular pressure was 13.6 (+/–2.7) mm Hg in the PD patients. No difference was found in either the superior or inferior outer retinal layer thickness of PD vs control eyes. The mean (SD) superior inner retinal layer thickness of PD vs control eyes was 88.79 (11.3) µm vs 103.5 (24.3) µm (P = .01), and the mean inferior inner retinal layer thickness was 89.83 (11.1) µm vs 104.0 (23.5) µm (P = .01).

Conclusions  The inner retinal layer is significantly thinner in PD patients than in healthy subjects. Idiopathic PD, distinct from glaucoma, needs to be considered in the differential diagnosis of retinal nerve fiber layer thinning.

Author Affiliations: Departments of Neurology, State University of New York Downstate Medical Center (Drs Hajee, Wolintz, Glazman, and Bodis-Wollner), Parkinson Disease and Related Disorders Center of Excellence, State University of New York Downstate (Dr Bodis-Wollner) and Kingsbrook Jewish Medical Center (Dr Bodis-Wollner); and Departments of Ophthalmology, State University of New York Downstate Medical Center (Drs Hajee, March, Lazzaro, Wolintz, Shrier, and Bodis-Wollner), Long Island College Hospital (Drs Hajee, March, Lazzaro, and Shrier), and Kingsbrook Jewish Medical Center (Drs Hajee and Wolintz), Brooklyn, New York.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Biomarkers for Parkinson's Disease
Sherer
Sci Transl Med 2011;3:79ps14-79ps14.
FULL TEXT  

Current Aspects of Cognitive Neurophysiology of Parkinson Disease: An Introduction
Bodis-Wollner
Clin EEG Neurosci 2010;41:68-75.
ABSTRACT | FULL TEXT